Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

rate, the Company has proposed an amended trial to continue its interest in the relapsed setting.

An agreement has been reached with the FDA on modifications to Vion Study CLI-037. The revised study includes a lower dose of Cloretazine(R) (VNP40101M) in the experimental arm of the trial and prophylactic therapy with antibiotics, antifungals and growth factors for all patients. In order to maintain the Special Protocol Assessment (SPA) with the FDA for this trial, the next step is to submit an SPA to the FDA with these modifications before recommencing the trial.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center at San Antonio, and lead investigator on the Cloretazine(R) clinical program stated, "Cloretazine(R) has recently shown very significant single agent activity in a the difficult to treat elderly AML patient population. It is important that we now establish the optimal dosing schedule in combination with other chemotherapeutic agents, such as cytarabine." He concluded, "Modifications to this Phase III trial in patients with relapsed AML will allow us to examine a combination schedule that should maintain the activity observed in the initial portion of the study with an acceptable marrow toxicity profile."

The Company also announced plans to file an abstract on data from Vion Study CLI-037 for the Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in June 2008.

Ann Cahill, Vice President, Clinical Development, commented, "Cloretazine(R) (VNP40101M) is an active agent in AML, and we continue to believe that it will have clinical utility in both the frontline and second line settings, as either a single agent or in combination with other therapies."

The Company has announced previously that it plans to file a New Drug Application with the FDA in 2008 based on a pivotal Phase II study of Cloretazine(R) (VNP40101M) as a single agent in eld
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that James ... has been elected to the Company,s Board of Directors, ... Anderson , Executive Chairman of CryoLife, stated, "Since joining the ... excellent leader who is well positioned to maximize CryoLife,s ...
(Date:10/22/2014)... LOUIS , Oct. 21, 2014  Early ... often subtle or unnoticed, but new technology, coupled ... outcomes and leading to earlier detection of eye ... affects 29 million Americans. If left untreated, these ... even blindness. Recently, optometric researchers ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Reportlinker.com announces that a new market research report ... - Drugs, Markets and Companies ... role of neuroprotection in acute disorders such as stroke ... in chronic diseases such as neurodegenerative disorders because many ...
... 2010 The Coordination for the Improvement of Personnel ... ceremony, celebrating the 10th anniversary of Portal de Periodicos. ... other international publishers who are part of the Portal. ... with access to its Micromedex® solutions, which include evidence-based ...
Cached Medicine Technology:Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 2Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 3Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 4Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 5Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 6Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 7Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 8Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 9Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 10Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 11Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 12Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 13Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 14Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 15Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 16Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 17Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 18Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 19Reportlinker Adds Neuroprotection - Drugs, Markets and Companies 20Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content 2
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... ATLANTA, Ga. (PRWEB) October 20, 2014 ... networking and relationship-marketing firm, announced today that William ... been named the 2014 ISE® Luminary Leadership Award ... celebrates the achievements of an outstanding leader and ... stewardship and contributions in advancing the information security ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... the Second Fiscal ... Quarter ... Fiscal 2008 Guidance, MOUNTAIN VIEW, Calif., Oct. 25 Pharsight,Corporation (OTC Bulletin ... drug development, today,announced financial results for its second quarter of fiscal 2008, ended,September ...
... kids missed back-to-school crush, they can still get the ... News) -- At the beginning of every school year, ... vaccine, with demand sometimes outpacing supply. , It doesn,t ... potentially lifesaving shot is available year-round. , While August ...
... Trial to Evaluate an Immunomodulatory Cell Therapy Product For ... October 25, 2007 The Juvenile Diabetes Research ... (NASDAQ:OSIR) to support a Phase II clinical trial using ... regenerate insulin-producing cells in patients newly diagnosed with type ...
... Oct. 25 John W. Walsh, president of ... the 53rd International,Respiratory Congress of the American Association ... AARC is a 43,000-member association,representing respiratory therapists involved ... ages who suffer a range of respiratory illness,including ...
... MELVILLE, N.Y., Oct. 25 Gentiva Health,Services, Inc. (Nasdaq: ... health and related services, announced today that it is,scheduled ... November 7,2007 at the CIBC World Markets 18th Annual ... available to the public via a live audio web ...
... In its first-ever,single-topic special issue, the Harvard ... offers advice aimed at unscrambling the mixed,messages about ... on nutrition, its recommendations include:, -- You ... with exercise,fruits and vegetables are the closest thing ...
Cached Medicine News:Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 2Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 3Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 4Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 5Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 6Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 7Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 8Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 9Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 10Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 11Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 12Health News:Meningitis Shot Available, Effective Year-Round 2Health News:Meningitis Shot Available, Effective Year-Round 3Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:Alpha-1 Foundation President to Give Keynote Address at 53rd Annual Respiratory Congress of the AARC Foundation and Activities 2Health News:Alpha-1 Foundation President to Give Keynote Address at 53rd Annual Respiratory Congress of the AARC Foundation and Activities 3Health News:Gentiva(R) Health Services to Present November 7 at CIBC Healthcare Conference in New York 2Health News:Gentiva(R) Health Services to Present November 7 at CIBC Healthcare Conference in New York 3Health News:All About Heart-Healthy Eating: The Harvard Heart Letter Devotes an Issue to Nutrition 2
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Medicine Products: